Business
HLS Therapeutics to Participate in Upcoming Virtual Non-Deal Roadshow on February 25, 2021
HLS Therapeutics to Participate in Upcoming Virtual Non-Deal Roadshow on February 25, 202...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Therapeutics to Participate in Upcoming Virtual Non-Deal Roadshow on February 25, 2021\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n TORONTO\n \n ,\n \n Feb. 23, 2021\n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it will participate in an upcoming event as part of Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series. For this event, Renmark is focused on attracting participants in the\n \n Greater Boston\n \n area. Other interested parties are welcome to attend as well.\n \n \n \n \n February 25, 2021\n \n at\n \n 10:00 AM EST\n \n (\n \n 7:00 AM PST\n \n ). To register and attend this live event, please follow the link:\n \n https://talk-deck.com/info/live-register/?326!ut9dx30v1dy\n \n \n \n \n \n Gilbert Godin\n \n , Chief Executive Officer, and\n \n Tim Hendrickson\n \n , Chief Financial Officer, will deliver the Company's presentation followed by a live Q&A. Investors interested in participating in the event will need to register using the link above. As a reminder, registration for the live event may be limited, but access to the replay after the event will be on the Company's Investor website.\n \n \n \n To ensure smooth connectivity, please access the link using the latest version of Google Chrome.\n \n \n \n \n ABOUT HLS THERAPEUTICS INC.\n \n \n \n Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit:\n \n \n www.hl...